These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. A comparison of Ku0063794, a dual mTORC1 and mTORC2 inhibitor, and temsirolimus in preclinical renal cell carcinoma models. Zhang H; Berel D; Wang Y; Li P; Bhowmick NA; Figlin RA; Kim HL PLoS One; 2013; 8(1):e54918. PubMed ID: 23349989 [TBL] [Abstract][Full Text] [Related]
6. Dual PI3K/mTOR Inhibitors Induce Rapid Overactivation of the MEK/ERK Pathway in Human Pancreatic Cancer Cells through Suppression of mTORC2. Soares HP; Ming M; Mellon M; Young SH; Han L; Sinnet-Smith J; Rozengurt E Mol Cancer Ther; 2015 Apr; 14(4):1014-23. PubMed ID: 25673820 [TBL] [Abstract][Full Text] [Related]
7. Distinct signaling mechanisms of mTORC1 and mTORC2 in glioblastoma multiforme: a tale of two complexes. Jhanwar-Uniyal M; Gillick JL; Neil J; Tobias M; Thwing ZE; Murali R Adv Biol Regul; 2015 Jan; 57():64-74. PubMed ID: 25442674 [TBL] [Abstract][Full Text] [Related]
8. Loss of p27 Associated with Risk for Endometrial Carcinoma Arising in the Setting of Obesity. McCampbell AS; Mittelstadt ML; Dere R; Kim S; Zhou L; Djordjevic B; Soliman PT; Zhang Q; Wei C; Hursting SD; Lu KH; Broaddus RR; Walker CL Curr Mol Med; 2016; 16(3):252-65. PubMed ID: 26917264 [TBL] [Abstract][Full Text] [Related]
9. mTOR complex 2 regulates proper turnover of insulin receptor substrate-1 via the ubiquitin ligase subunit Fbw8. Kim SJ; DeStefano MA; Oh WJ; Wu CC; Vega-Cotto NM; Finlan M; Liu D; Su B; Jacinto E Mol Cell; 2012 Dec; 48(6):875-87. PubMed ID: 23142081 [TBL] [Abstract][Full Text] [Related]
10. Mechanistic Target of Rapamycin Complex 1 (mTORC1) and mTORC2 as Key Signaling Intermediates in Mesenchymal Cell Activation. Walker NM; Belloli EA; Stuckey L; Chan KM; Lin J; Lynch W; Chang A; Mazzoni SM; Fingar DC; Lama VN J Biol Chem; 2016 Mar; 291(12):6262-71. PubMed ID: 26755732 [TBL] [Abstract][Full Text] [Related]
11. Cytoplasmic sequestration of p27 via AKT phosphorylation in renal cell carcinoma. Kim J; Jonasch E; Alexander A; Short JD; Cai S; Wen S; Tsavachidou D; Tamboli P; Czerniak BA; Do KA; Wu KJ; Marlow LA; Wood CG; Copland JA; Walker CL Clin Cancer Res; 2009 Jan; 15(1):81-90. PubMed ID: 19118035 [TBL] [Abstract][Full Text] [Related]
12. A dual mTORC1 and mTORC2 inhibitor shows antitumor activity in esophageal squamous cell carcinoma cells and sensitizes them to cisplatin. Huang Y; Xi Q; Chen Y; Wang J; Peng P; Xia S; Yu S Anticancer Drugs; 2013 Oct; 24(9):889-98. PubMed ID: 23838676 [TBL] [Abstract][Full Text] [Related]
13. BCR/ABL regulates expression of the cyclin-dependent kinase inhibitor p27Kip1 through the phosphatidylinositol 3-Kinase/AKT pathway. Gesbert F; Sellers WR; Signoretti S; Loda M; Griffin JD J Biol Chem; 2000 Dec; 275(50):39223-30. PubMed ID: 11010972 [TBL] [Abstract][Full Text] [Related]
14. Prognostic relevance of the mTOR pathway in renal cell carcinoma: implications for molecular patient selection for targeted therapy. Pantuck AJ; Seligson DB; Klatte T; Yu H; Leppert JT; Moore L; O'Toole T; Gibbons J; Belldegrun AS; Figlin RA Cancer; 2007 Jun; 109(11):2257-67. PubMed ID: 17440983 [TBL] [Abstract][Full Text] [Related]
15. The synergistic inhibition of breast cancer proliferation by combined treatment with 4EGI-1 and MK2206. Wang H; Huang F; Wang J; Wang P; Lv W; Hong L; Li S; Zhou J Cell Cycle; 2015; 14(2):232-42. PubMed ID: 25607647 [TBL] [Abstract][Full Text] [Related]
16. Point mutations of the mTOR-RHEB pathway in renal cell carcinoma. Ghosh AP; Marshall CB; Coric T; Shim EH; Kirkman R; Ballestas ME; Ikura M; Bjornsti MA; Sudarshan S Oncotarget; 2015 Jul; 6(20):17895-910. PubMed ID: 26255626 [TBL] [Abstract][Full Text] [Related]
17. The endosomal sorting complex required for transport pathway mediates chemokine receptor CXCR4-promoted lysosomal degradation of the mammalian target of rapamycin antagonist DEPTOR. Verma R; Marchese A J Biol Chem; 2015 Mar; 290(11):6810-24. PubMed ID: 25605718 [TBL] [Abstract][Full Text] [Related]
18. Targeting PI3K and mTORC2 in metastatic renal cell carcinoma: new strategies for overcoming resistance to VEGFR and mTORC1 inhibitors. Figlin RA; Kaufmann I; Brechbiel J Int J Cancer; 2013 Aug; 133(4):788-96. PubMed ID: 23319457 [TBL] [Abstract][Full Text] [Related]
19. Rictor Undergoes Glycogen Synthase Kinase 3 (GSK3)-dependent, FBXW7-mediated Ubiquitination and Proteasomal Degradation. Koo J; Wu X; Mao Z; Khuri FR; Sun SY J Biol Chem; 2015 May; 290(22):14120-9. PubMed ID: 25897075 [TBL] [Abstract][Full Text] [Related]